Is a 96.8% result from VendorInvestigate comparable to 99.4% from Medutest?

Conditions: 96.8% · VendorInvestigate · 99.4% · Medutest.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

What is the actual trade-off, and does it matter at the scale I am working at?

96.8 and 99.4 are 2.6 percentage points apart, which sounds small until you restate it as impurity. VendorInvestigate is leaving 3.2 per cent of the detected area unassigned and Medutest 0.6 per cent — a factor of 5.33 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 96.8 and 99.4 are two measurements of slightly different quantities that happen to share a unit.

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mass shifts and what they usually mean

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

Worth being precise here: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

To be exact about it, integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you are ranking vendors, specify a method and have all samples tested at the same place.

In practice, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

More usefully, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.